CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity
Open Access
- 27 February 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 532
Abstract
CYP1A2, one of the most abundant hepatic cytochrome P450 enzymes, is involved in metabolism of several drugs and carcinogenic compounds. Data on the significance of CYP1A2 genetic polymorphisms in enzyme activity are highly inconsistent; therefore, the impact of CYP1A2 genetic variants (−3860G>A, −2467delT, −739T>G, −163C>A, 2159G>A) on mRNA expression and phenacetin O-dealkylation selective for CYP1A2 was investigated in human liver tissues and in psychiatric patients belonging to Caucasian populations. CYP1A2*1F, considered to be associated with high CYP1A2 inducibility, is generally identified by the presence of −163C>A polymorphism; however, we demonstrated that −163C>A existed in several haplotypes (CYP1A2*1F, CYP1A2*1L, CYP1A2*1M, CYP1A2*1V, CYP1A2*1W), and consequently, CYP1A2*1F was a much rarer allelic variant (0.4%) than reported in Caucasian populations. Of note, −163C>A polymorphism was found to result in an increase of neither mRNA nor the activity of CYP1A2. Moreover, hepatic CYP1A2 activity was associated with hepatic or leukocyte mRNA expression rather than genetic polymorphisms of CYP1A2. Consideration of non-genetic phenoconverting factors (co-medication with CYP1A2-specific inhibitors/inducers, tobacco smoking and non-specific factors, including amoxicillin+clavulanic acid therapy or chronic alcohol consumption) did not much improve genotype–phenotype estimation. In conclusion, CYP1A2-genotyping is inappropriate for the prediction of CYP1A2 function; however, CYP1A2 mRNA expression in leukocytes can inform about patients’ CYP1A2-metabolizing capacity.Keywords
Funding Information
- Financial Ministry of Hungary (VEKOP-2.3.3-15-2017-00014)
- National Research, Development and Innovation Fund of Hungary (2020-1.1.2-PIACI-KFI-2020-00021)
This publication has 72 references indexed in Scilit:
- Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2012
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- Pathway-Targeted Pharmacogenomics of CYP1A2 in Human LiverFrontiers in Pharmacology, 2010
- Analysis of humanCYP1A1andCYP1A2genes and their shared bidirectional promoter in eight world populationsHuman Mutation, 2009
- Hormonal regulation of CYP1A expressionDrug Metabolism Reviews, 2009
- Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2The AAPS Journal, 2009
- A Common Regulatory Region Functions Bidirectionally in Transcriptional Activation of the Human CYP1A1 and CYP1A2 GenesMolecular Pharmacology, 2006
- Acute Liver Failure Due To Amoxicillin and Amoxicillin/ClavulanateDigestive Diseases and Sciences, 2005
- Cytochrome P-450 mRNA Expression in Human Liver and Its Relationship with Enzyme ActivityArchives of Biochemistry and Biophysics, 2001
- Expression of Cytochrome P450 mRNAs in the Colon and the Rectum in Normal Human SubjectsBiochemical and Biophysical Research Communications, 1995